PRTC
Puretech Health

114
Mkt Cap
$464.34M
Volume
7,715.00
52W High
$20.00
52W Low
$13.30
PE Ratio
10.55
PRTC Fundamentals
Price
$18.15
Prev Close
$19.21
Open
$18.20
50D MA
$16.93
Beta
0.38
Avg. Volume
1,267.23
EPS (Annual)
$2.10
P/B
1.23
Loading...
Loading...
News
all
press releases
PureTech Health (LON:PRTC) Trading Up 0.7% - Still a Buy?
PureTech Health (LON:PRTC) Trading 0.7% Higher - What's Next...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today...
Business Wire·14d ago
News Placeholder
PureTech Health (NASDAQ:PRTC) Trading Down 0.7% - Time to Sell?
PureTech Health (NASDAQ:PRTC) Shares Down 0.7% - What's Next...
MarketBeat·1mo ago
News Placeholder
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today...
Business Wire·1mo ago
News Placeholder
PureTechs Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes...
Business Wire·2mo ago
News Placeholder
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today...
Business Wire·3mo ago
News Placeholder
What Makes PureTech Health (PRTC) a New Buy Stock
PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4mo ago
<
...
1
>

Latest PRTC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.